Italian nutraceutical developer Cor.Con. International earns a finalist spot in the Finished Formulation category with a clinically validated supplement designed to mitigate antiepileptic drug side-effects in children.
The shortlist for the CPHI Pharma Awards 2026 celebrated outstanding accomplishments across fifteen core categories in the international pharmaceutical landscape during CPHI Milan at Fiera Milano. Among the top contenders in the prestigious Finished Formulation category, Italian formulation and development specialist Cor.Con. International secured a finalist spot with its patented paediatric innovation, Epilamba Junior.
The nomination highlights a growing industry shift toward non-pharmacological, supportive strategies that address the secondary burdens of chronic therapies. Chronic paediatric conditions like epilepsy require long-term pharmacological management. While antiepileptic drugs remain essential for seizure control, they frequently trigger side effects that affect a child’s daily life, learning abilities, and emotional stability. By introducing a scientifically validated food supplement designed to mitigate these adverse effects without altering drug efficacy, the Italian company has gained major international attention from healthcare professionals and industry experts alike.
Addressing an Unmet Need in Paediatric Epilepsy Care
Epilepsy stands as one of the most prevalent neurological conditions globally, affecting over 70 million individuals. In Europe alone, approximately 900,000 children and adolescents live with active epilepsy, with around 130,000 new paediatric cases diagnosed each year. Standard antiepileptic drugs are fundamental to controlling seizures, yet they often come with heavy trade-offs. Young patients frequently experience chronic fatigue, cognitive fog, mood fluctuations, sleep disruptions, and gastrointestinal issues.
These ongoing complications influence academic performance, social integration, and psychological well-being. Furthermore, physical discomfort and behavioural changes directly lower treatment compliance, creating stress for families and clinicians. While pharmaceutical research continuously refines active drug molecules, a gap has remained in clinical practice: managing treatment-related adverse effects without adding pharmacological complexity.
Epilamba Junior was developed precisely to bridge this clinical gap. Created through a close collaboration between the company’s scientific team and the Food and Drug Department at the University of Parma, the formulation offers a structured, non-pharmacological strategy. Rather than targeting seizure frequency directly, the product focuses on supporting the paediatric patient’s overall functional health. It aims to improve quality of life during long-term antiepileptic regimens, helping young patients maintain their daily routines, school engagement, and emotional balance.
Solid Science and Innovation Behind the Formulation
What distinguishes Epilamba Junior from general supportive supplements is its strict adherence to pharmaceutical-grade research standards. The development team designed the product around three clear physiological parameters: avoiding interference with the pharmacodynamics of antiepileptic drugs, preventing alterations to drug pharmacokinetics, and preserving therapeutic outcomes. This approach guarantees that the supplement can be administered safely alongside complex AED polytherapies.
The product features a combination of botanicals and essential nutrients, protected under international patent.
To validate its real-world clinical utility, Epilamba Junior underwent a dedicated clinical trial conducted at the Paediatric Neurology and Muscular Diseases Unit of the Istituto Giannina Gaslini in Genoa. The peer-reviewed clinical findings were recently published in the journal Global Pediatrics. The trial evaluated paediatric patients on stable antiseizure mono- and polytherapy over a six-month period, measuring both safety and symptomatic changes.
The published results confirmed that adding the daily supplement did not modify seizure frequency or semiology, proving complete compatibility with standard medications. Simultaneously, patients demonstrated statistically significant improvements in adverse effect profiles. Clinicians observed improved attention spans, greater emotional equilibrium, better sleep quality, and reduced gastrointestinal discomfort. To support long-term adherence in young children, the product is delivered in convenient, single-dose sticks that are free from gluten, lactose, and added sugars.
The Evolution in Modern Medical Care
The recognition of Epilamba Junior at the CPHI Pharma Awards 2026 reflects a broader evolution in modern medical care: prioritising overall patient well-being alongside disease management. By developing a first-in-class, patented solution for treatment-related complications, the company establishes a new category within supportive paediatric neurology.
This development aligns with a fundamental transformation occurring across global healthcare pathways. Modern therapeutics increasingly recognize that managing chronic conditions effectively requires looking beyond primary symptom suppression alone. In complex paediatric fields, clinical success relies heavily on sustaining the patient’s overall physical, cognitive, and emotional equilibrium throughout the treatment journey.
As clinical research continues to explore integrated strategies, the broader medical community moves closer to a comprehensive model of care where therapeutic efficacy and human well-being advance hand in hand.
